

BMI CHART

Hiranandani Fortis Hospital

Mini Seashore Road, Sector 10 - A, Vashi, Navi Mumbai - 400 703.

Tel.: +91-22-3919 9222 Fax: +91-22-3919 9220/21

Email: vashi@vashihospital.com

Signature

Date: 12 /11 / 00/2

Nom	M.		2	no l	, -, f		D	٨	1					3									1_3		
ivame	ə: <u>_</u> Mٍu	-	O	101	0		N	od	non	٧.			_Ag	e: <u>3</u>	4_	yrs			Sex	M/	F		×		
BP:	10/70		_	Hei	ght (cms): /1	to	C	D	W	'eiah	ıt(ka	s):	G	6.	3 K	9	RM	1.	× 2	Š			
	ma cff	49-	= 5		70 B		()	25		-(9	·/·_				1	DIVI		10)			
WE	IGHT lbs	10	0 105	100	115	120	125	130	135	140	145	150	155	160	165	170	175	180	185	190	195	200	205	210	215
	kgs	45.	_			54.5	56.8	-		63.6	65.9	68.2	77	72.7		77.3	79.5	81.8	84.1	86.4	88.6	90.9	93.2	95.5	97.7
	SHT in/cm	L	_	derwe				Hea	lthy				Ove	rweig	ht			Obe	se			Ext	reme	ly Obe	se
	- 152.4	-	20			-			1	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42
	- 154.9	18					23		1		27	28	29	30	31	32	33	34	35	36	36	37	38	39	40
	- 157.4	18	-		-		22				26	27	28	29	30	31	32	33	33	34	35	36	37	38	39
	- 160.0	17	_			-	22			_		26	27	28	29	30	31	32	32	33	34	35	36	37	38
	- 162.5	17	18	-	_	-	21	1					26	27	28	29	30	31	31	32	33	34	35	36	37
	- 165.1	16	17	18	-		20						25	26	27	28	29	30	30	31	32	33	34	35	35
	- 167.6	16	17	17	-	-	20					24		25	26	27	28	29	29	30	31	32	33	34	34
	- 170.1	15	16	17	18		19								25	26	27	28	29	29	30	31	32	33	33
	- 172.7	14	16	16	17	18		19						24		25	26	27	28	28	29	30	31	32	32
	- 176.2	14	15	16 15	17	17	-	19			_		-	23		1		26	27	28	28	29	30	31	31
	- 177.8	14	14	15	16 16	17	18	-	19			-	-	23			1	25	26	27	28	28	29	30	30
	- 180.3	13	14	14	15	16	17	18		19	-		1	22				122	25	26	27	28	28	29	30
	- 182.8	13	13	14	15	16 15	17	17	18	19		=		21						25	26	27	27	28	29
	- 185.4	12	13	14	14	15	16 16	17 16	17	18	-	A COLUMN TWO	The real Property lies	21					Control of the	570.7	100000000000000000000000000000000000000	26	27	27	28
	- 187.9	12	13	13	14	15			17	18			-	20			- 4	270,77	9800			25	26	27	27
	190.5	12	12	13	14	14	15 15	16	16	17	18			20								-	25	26	26
6'4" -	193.0	12	112	13	14	14	15	15	16	17	17	18	18	19	20	20團	21	22	22	23	23	24	25	25	26
D	4 NI - 4 -	*2																	9:						
DOC	tors Note	<u>s:</u>	ž)																					•	
,	2		(4)								2			5.45	,							5.			
				-07				-										****							
-				ran																					
													i.												
2024					F 8																				
			ě									n e										-			
	-						-					-1		*		100									1
																	•								
i.e.												8													

Hiranandani Healthcare Pvt. Ltd.

Mini Sca Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220

Emergency: 022 - 39199100 | Ambulance: 1255 For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D





(A 1) Fortis Network Hospital)

	2254545	Date	12/11/2	022	
UHID	2354747	Sex	Male	Age	34
Name	Mr. Sushil Pradhan		h Check-	up	4
OPD	Ophthal 14	Healt	ii Chech		

Name	Mr. Sushil Pradhan	Health Check-up
OPD Wr. No		Drug allergy: -> Not kun Sys illness: -> No
MC> No	o. Uitel Ville	or 6/6
	Ro-> No-> No->	Phen 6/6 Phen 6/6
	Jol.	C > 15.4
	PCh-Tong	1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D





(A 1) Forfis Network Hospital)

UHID	2354747	Date	12/11/20	022	
Name	Mr. Sushil Pradhan	Sex	Male	Age	34
OPD	Dental 12	Healtl	h Check-ı	1 p	

Drug allergy: Sys illness:

bleeding gums. 1) Stain+ Calculus + +

2) Crowdiy & lower anterins.

Ach) Oral propylaxis 2) Ortlo Re







PATIENT NAME: MR. MR.SUSHIL PRADHAN

PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO: 0022VK002643 AGE: 34 Years

SEX: Male

ABHA NO: REPORTED:

12/11/2022 15:37:13

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

DRAWN: 12/11/2022 09:54:00

RECEIVED: 12/11/2022 09:56:42

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status

Final

Results

Biological Reference Interval

Units

SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

T3

135.5

80 - 200

ng/dL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY T4

5.1 - 14.1

µg/dL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY TSH (ULTRASENSITIVE)

2.110


0.270 - 4.200

µIU/mL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

Interpretation(s)













PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO:

0022VK002643

AGE : 34 Years

ABHA NO:

DRAWN: 12/11/2022 09:54:00

RECEIVED: 12/11/2022 09:56:42

REPORTED:

12/11/2022 15:37:13

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SFIF

CLINICAL INFORMATION:

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status

Final

Results

Biological Reference Interval

Units

SPECIALISED CHEMISTRY - TUMOR MARKER

PROSTATE SPECIFIC ANTIGEN, SERUM

PROSTATE SPECIFIC ANTIGEN

0.250

< 1.4

ng/mL

METHOD: ELECTROCHEMILUMINESCENCE, SANDWICH IMMUNOASSAY

Interpretation(s)

PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis. PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the female patient.

- It a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.

- It a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.

It a solitable marker for monitoring or patients with prostate cancer and it is better to be used in conjunction with other diagnostic procedures.
 Serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in

detecting residual disease and early recurrence of tumor.

- Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.

- Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA (false positive) levels persisting up to 3 weeks.

case positive) levels persisting up to 3 weeks.

- As per American urological guidelines, PSA screening is recommended for early detection of Prostate cancer above the age of 40 years. Following Age specific reference range can be used as a guide lines-

Age of male Reference range (ng/ml)

40-49 years 50-59 years 0-2.5

0-3.5

60-69 years 70-79 years 0-6.5

(* conventional reference level (< 4 ng/ml) is already mentioned in report, which covers all agegroup with 95% prediction interval)

References- Teitz ,textbook of clinical chemiistry, 4th edition) 2.Wallach's Interpretation of Diagnostic Tests

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Dr. Swapnil Sirmukaddam

(2) irmbaddam 786

Consultant Pathologist

CIN - U74899PB1995PLC045956

BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4, KHARGHAR NAVI MUMBAI, 410210 MAHARASHTRA, INDIA Tel: 9111591115,







Scan to View Report

Page 2 Of 2 Patient Ref. No. 2200000080807







PATIENT NAME: MR. MR.SUSHIL PRADHAN

PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO: 0022VK002643

AGE: 34 Years

SEX: Male

ABHA NO:

DRAWN: 12/11/2022 09:54:00

RECEIVED: 12/11/2022 09:56:42

REPORTED:

12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 · BILLNO-1501220PCR056893

Test Report Status

Final

Results

Biological Reference Interval

Units

KIDNEY PANEL - 1

BLOOD UREA NITROGEN (BUN), SERUM


BLOOD UREA NITROGEN

7

6 - 20

mg/dL

METHOD : UREASE - UV



CREATININE

0.68

Low 0.90 - 1.30

mg/dL

AGE

METHOD: ALKALINE PICRATE KINETIC JAFFES

34

125.09

years

mL/min/1.73m

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

GLOMERULAR FILTRATION RATE (MALE)

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email: -



Scan to View Details



Scan to View Report









PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO: 0022VK002643

AGE: 34 Years SEX: Male

ABHA NO:

DRAWN: 12/11/2022 09:54:00

RECEIVED: 12/11/2022 09:56:42

REPORTED:

12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD


BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status

Results

Biological Reference Interval

Units



		(20,000)		
	BUN/CREAT RATIO			
	BUN/CREAT RATIO	10.29		5.00 - 15.
	METHOD: CALCULATED PARAMETER			
	URIC ACID, SERUM			
	URIC ACID	4.8		3.5 - 7.2
X	METHOD: URICASE UV			
	TOTAL PROTEIN, SERUM			
	TOTAL PROTEIN	8.4	High	6.4 - 8.2
	METHOD : BIURET			
	ALBUMIN, SERUM			
	ALBUMIN	4.8		3.4 - 5.0
	METHOD : BCP DYE BINDING			
	GLOBULIN			
	GLOBULIN	3.6		2.0 - 4.1
357	METHOD: CALCULATED PARAMETER			

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM

METHOD: ISE INDIRECT

POTASSIUM, SERUM

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -



139

3.62

Scan to View Details



Scan to View Report

136 - 145

3.50 - 5.10



mg/dL

g/dL

g/dL

g/dL

mmol/L

mmol/L







PATIENT ID: FH.2354747

DRAWN: 12/11/2022 09:54:00

CLIENT PATIENT ID: UID:2354747

ACCESSION NO: 0022VK002643

AGE: 34 Years

SEX: Male

ABHA NO:

RECEIVED: 12/11/2022 09:56:42

REPORTED:

12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status <u>Final</u>	Results	Biological Reference Interval	Units
METHOD: ISE INDIRECT			
CHLORIDE, SERUM METHOD: ISE INDIRECT	103	98 - 107	mmol/L
Interpretation(s)	ũ		
PHYSICAL EXAMINATION, URINE			
COLOR	DALE VELLOW		

PALE YELLOW

METHOD : PHYSICAL

APPEARANCE

CLEAR

METHOD: VISUAL

CHEMICAL EXAMINATION, URINE

7.0

4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD SPECIFIC GRAVITY

1.020

1.003 - 1.035

METHOD: REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE

GLUCOSE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD

KETONES

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

BLOOD

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN

BILIRUBIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

UROBILINOGEN

NORMAL

NORMAL

METHOD: REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION)

NITRITE NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE

LEUKOCYTE ESTERASE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S)

0 - 1

0-5

/HPF

METHOD: MICROSCOPIC EXAMINATION

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,

SECTOR 10.

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956



Scan to View Details



Scan to View Report









PATIENT NAME: MR. MR.SUSHIL PRADHAN

CLIENT PATIENT ID: UID:2354747 PATIENT ID: FH.2354747

ACCESSION NO : 0022VK002643

AGE: 34 Years SEX: Male

ABHA NO :

DRAWN: 12/11/2022 09:54:00

RECEIVED: 12/11/2022 09:56:42

REPORTED:

12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:2354747 OLD UHID -FHL34.228221 REONO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
EPITHELIAL CELLS METHOD: MICROSCOPIC EXAMINATION	1-2	0-5	/HPF
CASTS METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		
CRYSTALS METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		
BACTERIA METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	
YEAST METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	
REMARKS	URINARY MICROSCON CENTRIFUGED SEDIM	PIC EXAMINATION DONE ON U	RINARY
Interpretation(s)			

Interpretation(s)

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)
Causes of decreased level include Liver disease, SIADH.

CREATININE EGFR- EPI-

GFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test. Creatinine is a muscle waste product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined. A GFR of 60 or higher is in the normal range.

A GFR below 60 may mean kidney disease. A GFR of 15 or lower may mean kidney failure.

Estimated GFR (GFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Renal Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone.

The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated GFR and serum creatinine, and a different relationship for age, sex and race. The equation was reported to perform better and with less bias than the MDRD Study equation, especially in patients with higher GFR. This results in reduced misclassification of CKD.

The CKD-EPI creatinine equation has not been validated in children & will only be reported for patients = 18 years of age. For pediatric and childrens, Schwartz Pediatric Bedside eGFR (2009) formulae is used. This revised "bedside" pediatric eGFR requires only serum creatinine and height.

Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956







Scan to View Report









PATIENT NAME: MR. MR. SUSHIL PRADHAN

PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO:

0022VK002643 AGE:

34 Years

SEX: Male

RECEIVED: 12/11/2022 09:56:42

ABHA NO:

REPORTED:

12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

DRAWN: 12/11/2022 09:54:00

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status

Final

Results

Biological Reference Interval

HAEMATOLOGY

CBC-5, EDTA WHOLE BLOOD

MORPHOLOGY

RBC

METHOD: MICROSCOPIC EXAMINATION

WBC

METHOD: MICROSCOPIC EXAMINATION

PLATELETS

METHOD: MICROSCOPIC EXAMINATION

PREDOMINANTLY NORMOCYTIC NORMOCHROMIC, MILD ANISOCYTOSIS

NORMAL MORPHOLOGY

ADEQUATE

ERYTHROCYTE SEDIMENTATION RATE

(ESR), WHOLE BLOOD

E.S.R

04

0 - 14

mm at 1 hr

CBC-5, EDTA WHOLE BLOOD

METHOD: WESTERGREN METHOD

BLOOD COUNTS, EDTA WHOLE BLOOD

)	HEMOGLOBIN (HB)	14.9		13.0 - 17.0	g/dL
	METHOD: SPECTROPHOTOMETRY			¥	
	RED BLOOD CELL (RBC) COUNT	4.99		4.5 - 5.5	mil/μL
	METHOD: ELECTRICAL IMPEDANCE				
7	WHITE BLOOD CELL (WBC) COUNT	5.50	į.	4.0 - 10.0	thou/µL
	METHOD: DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DHSS)CY	TOMETRY			AND DOWNSON * SALE
	PLATELET COUNT	167		150 - 410	thou/µL
	METHOD: ELECTRICAL IMPEDANCE				5000007A #500
	RBC AND PLATELET INDICES				
	HEMATOCRIT (PCV)	44.0		40 - 50	%
	METHOD: CALCULATED PARAMETER				
	MEAN CORPUSCULAR VOLUME (MCV)	88.3		83 - 101	fL
	METHOD: CALCULATED PARAMETER				

29.8

33.8

METHOD: CALCULATED PARAMETER

CONCENTRATION(MCHC)

METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN

SRL LtdHIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,

MEAN CORPUSCULAR HEMOGLOBIN (MCH)

SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email: -

Scan to View Details



27.0 - 32.0

31.5 - 34.5

Scan to View Report



pg

g/dL







PATIENT NAME: MR. MR.SUSHIL PRADHAN

PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO:

0022VK002643

AGE: 34 Years

SEX: Male

RECEIVED: 12/11/2022 09:56:42

ABHA NO: REPORTED:

12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

DRAWN: 12/11/2022 09:54:00

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status	<u>Final</u>	Results		Biological Reference Interv	al
RED CELL DISTRIBUTION METHOD: CALCULATED PARAM		16.4	High	11.6 - 14.0	%
MENTZER INDEX		17.7			
 MEAN PLATELET VOLUMI METHOD : CALCULATED PARAM 		8.2		6.8 - 10.9	fL
WBC DIFFERENTIAL C				ø	
NEUTROPHILS METHOD: FLOW CYTOMETRY		62		40 - 80	%
LYMPHOCYTES METHOD: FLOW CYTOMETRY		30		20 - 40	%
MONOCYTES METHOD: FLOW CYTOMETRY		6		2 - 10	%
EOSINOPHILS METHOD: FLOW CYTOMETRY		2		1 - 6	%
BASOPHILS METHOD: FLOW CYTOMETRY		0		0 - 2	%
ABSOLUTE NEUTROPHIL METHOD: CALCULATED PARAM	ETER	3.41		2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE METHOD : CALCULATED PARAM	ETER	1.65		1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE CO	ETER	0.33		0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL (METHOD : CALCULATED PARAMI	ETER	0.11		0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL CO METHOD: CALCULATED PARAMI	ETER	0	Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTT METHOD : CALCULATED PARAME		2.1			

Interpretation(s)

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:
Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.


SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







Scan to View Report









' PATIENT ID :

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO:

0022VK002643

AGE: 34 Years

ABHA NO:

DRAWN: 12/11/2022 09:54:00

RECEIVED: 12/11/2022 09:56:42

REPORTED:

12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status

Einal

Results

Biological Reference Interval

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, Spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

REFERENCE

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. RBC AND PLATELET INDICES-

RBC AND PLATELET INDICESMentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

WBC DIFFERENTIAL COUNT- Ine optimal threshold of 3.3 for NLR snowed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

IMMUNOHAEMATOLOGY

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE B

METHOD: TUBE AGGLUTINATION

RH TYPE

POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for

The test is performed by both forward as well as reverse grouping methods.

BIO CHEMISTRY

Scan to View Details

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL

140

< 200 Desirable

mg/dL

200 - 239 Borderline High >/= 240 High

mg/dL

METHOD: ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE TRIGLYCERIDES

109

< 150 Normal 150 - 199 Borderline High

200 - 499 High

>/=500 Very High

Page 7 Of 15

Patient Ref. No. 2200000080807



Scan to View Report



SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MR. MR.SUSHIL PRADHAN

PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

: 'ACCESSION NO: 0022VK002643 AGE: 34 Years

SEX: Male ABHA NO:

DRAWN: 12/11/2022 09:54:00

RECEIVED: 12/11/2022 09:56:42

REPORTED: 12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD


BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status <u>Final</u>	Results Biological Reference Interval			
METHOD : ENZYMATIC ASSAY				
HDL CHOLESTEROL METHOD: DIRECT MEASURE - PEG	37	Low	< 40 Low >/=60 High	mg/dL
LDL CHOLESTEROL, DIRECT . METHOD: DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT	77		< 100 Optimal 100 - 129 Near or above optim 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL al
NON HDL CHOLESTEROL METHOD: CALCULATED PARAMETER	103	-	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
CHOL/HDL RATIO METHOD: CALCULATED PARAMETER	3.8		3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO METHOD: CALCULATED PARAMETER	2.1		0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate F >6.0 High Risk	Risk
VERY LOW DENSITY LIPOPROTEIN METHOD: CALCULATED PARAMETER	21.8		= 30.0</td <td>mg/dL</td>	mg/dL

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,
NAVI MUMBAI, 400703
MAHARASHTRA, INDIA
Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956







Scan to View Report









PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO: 0022VK002643 AGE: 34 Years

SEX: Male

ABHA NO:

REPORTED:

12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

: · DRAWN: 12/11/2022 09:54:00

RECEIVED: 12/11/2022 09:56:42

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD


BILLNO-1501220PCR056893 BILLNO-1501220PCR056893


Test Report Status

Final

Results

Biological Reference Interval





HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email: -



Scan to View Details



Scan to View Report









PATIENT ID: FH.2354747 CLIENT PATIENT ID: UID:2354747

ACCESSION NO: 0022VK002643 AGE: 34 Years SEX: Male ABHA NO:

DRAWN: 12/11/2022 09:54:00 RECEIVED: 12/11/2022 09:56:42 REPORTED: 12/11/2022 13:16:42

REFERRING DOCTOR: SELF CLIENT NAME : FORTIS VASHI-CHC -SPLZD


CLINICAL INFORMATION:


UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status Results **Final Biological Reference Interval**






LIVER FUNCTION PROFILE, SERUM

Email: -

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956















PATIENT NAME: MR. MR.SUSHIL PRADHAN

PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO: 0022VK002643 AGE: 34 Years

SEX: Male

ABHA NO:

DRAWN: 12/11/2022 09:54:00

RECEIVED: 12/11/2022 09:56:42

REPORTED: 12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

'UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status Final	Results ·		Biological Reference Interv	21
			-1010 Judi Reference Interv	aı
BILIRUBIN, TOTAL METHOD: JENDRASSIK AND GROFF	0.56		0.2 - 1.0	mg/dL
BILIRUBIN, DIRECT METHOD: JENDRASSIK AND GROFF	0.09		0.0 - 0.2	mg/dL
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	0.47		0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: BIURET	8.4	High	6.4 - 8.2	g/dL
ALBUMIN METHOD: BCP DYE BINDING	4.8		3.4 - 5.0	g/dL
GLOBULIN METHOD: CALCULATED PARAMETER	3.6		2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	1.3		1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: UV WITH P5P	18		15 - 37	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV WITH P5P	27		< 45.0	U/L
ALKALINE PHOSPHATASE METHOD: PNPP-ANP	66		30 - 120	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	14	Low	15 - 85	U/L
LACTATE DEHYDROGENASE METHOD: LACTATE -PYRUVATE	165		100 - 190	U/L
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR) METHOD: HEXOKINASE	100	High	74 - 99	mg/dL

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,

SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email : -


. .







Scan to View Report









PATIENT NAME: MR. MR.SUSHIL PRADHAN

PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO:

0022VK002643

AGE: 34 Years

SEX: Male

ABHA NO:

12/11/2022 13:16:42

DRAWN: 12/11/2022 09:54:00

RECEIVED: 12/11/2022 09:56:42

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD


BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status

Final

Results

Biological Reference Interval



GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C

5.2

Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4

Diabetics: > or = 6.5ADA Target: 7.0

Action suggested: > 8.0

METHOD: HB VARIANT (HPLC)

METHOD: CALCULATED PARAMETER

ESTIMATED AVERAGE GLUCOSE(EAG)

102.5

< 116.0

mg/dL

%

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email: -



Scan to View Details



Scan to View Report









PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO:

0022VK002643 AGE: 34 Years SEX: Male

ABHA NO:

REPORTED:

12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

RECEIVED: 12/11/2022 09:56:42

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893


DRAWN: 12/11/2022 09:54:00

Test Report Status

Final

Results

Biological Reference Interval



LIPID PROFILE, SERUM-Serum cholesterol is a blood test that can provide valuable information for the risk of coronary artery disease This test can help determine your risk of the build up of plaques in your arteries that can lead to narrowed or blocked arteries throughout your body (atherosclerosis). High cholesterol levels usually don't cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels often are a significant risk factor for heart disease and important for diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn" triglyceride levels are a type or rat in the blood. When you eat, your body converts any calories it doesn triglyceride into triglycerides, which are stored in fat cells. High diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other provides valuable information for the assessment of coronary heart disease risk. It is done in fasting state.

High-density lipoprotein (HDL) cholesterol. This is sometimes called the ""good"" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open and blood flowing more freely. HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLDL). NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both primary

Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email: -







Scan to View Report

Page 13 Of 15 Patient Ref. No. 2200000080807







PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO:

0022VK002643

AGE: 34 Years

ABHA NO:

RECEIVED: 12/11/2022 09:56:42

REPORTED:

12/11/2022 13:16:42

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

DRAWN: 12/11/2022 09:54:00

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status

Final

Results

Biological Reference Interval

NON FASTING LIPID PROFILE includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol. It does not include triglycerides and may be best used in patients for whom fasting is difficult. LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

EINTER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that

AST is an enzyme found in various parts of the body. AST is found in the liver head with the liver head with

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatitis, obstruction of bile ducts, cirrhosis.

AST levels may also increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein-low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the Increased in

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Peacreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

glycosystetic memographic metals are lavored to monitor grycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes.

Identifying patients at increased risk for diabetes (prediabetes).

3.1dentifying patients at increased risk for diabetes (prediabetes). The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels. 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

HDAIC Estimation can get affected due to:

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

III.Iron deficiency anemia is reported to increase test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a Homozypous hemoglobinopathy. Enclosemine is recommended for testing of HbA1c.

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Email: -



Scan to View Details



Scan to View Report

Page 14 Of 15 Patient Ref. No. 2200000080807







PATIENT NAME: MR. MR.SUSHIL PRADHAN

PATIENT ID: FH.2354747 CLIENT PATIENT ID: UID:2354747

ACCESSION NO: 0022VK002643

AGE: 34 Years SEX: Male

ABHA NO :

12/11/2022 13:16:42

RECEIVED: 12/11/2022 09:56:42

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

DRAWN: 12/11/2022 09:54:00

UID:2354747 OLD UHID -FHL34.228221 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status

Einal

Results

Biological Reference Interval

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

Dr.Akta Dubey

Counsultant Pathologist

Dr. Rekha Nair, MD


Microbiologist

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956

Email: -







Scan to View Report

Page 15 Of 15 Patient Ref. No. 2200000080807







PATIENT NAME: MR. MR.SUSHIL PRADHAN

PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO:

0022VK002711 AGE: 34 Years

SEX: Male

ABHA NO:

REPORTED:

12/11/2022 14:19:07

DRAWN: 12/11/2022 12:35:00

RECEIVED: 12/11/2022 12:36:04

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR:

CLINICAL INFORMATION:

UID:2354747 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Results **Test Report Status** Final

Biological Reference Interval

Units

BIO CHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA


PPBS(POST PRANDIAL BLOOD SUGAR)

101

70 - 139

mg/dL

METHOD: HEXOKINASE



Interpretation(s)
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics with the post prandial glucose level may be seen due to effect of Oral Hypoglycaemics with the post prandial glucose level may be seen due to effect of Oral Hypoglycaemics with the post prandial glucose level may be seen due to effect of Oral Hypoglycaemics with the post prandial glucose level may be seen due to effect of Oral Hypoglycaemics with the post prandial glucose level may be seen due to effect of Oral Hypoglycaemics with the post prandial glucose level may be seen due to effect of Oral Hypoglycaemics with the post prandial glucose level may be seen due to effect of Oral Hypoglycaemics with the post prandial glucose level may be seen due to effect of Oral Hypoglycaemics with the post prandial glucose level may be seen due t

End Of Report Please visit www.srlworld.com for related Test Information for this accession

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -







Scan to View Report









PATIENT NAME: MR. MR.SUSHIL PRADHAN

PATIENT ID:

FH.2354747

CLIENT PATIENT ID: UID:2354747

ACCESSION NO: 0022VK002711 AGE: 34 Years

ABHA NO:

DRAWN: 12/11/2022 12:35:00

RECEIVED: 12/11/2022 12:36:04

REPORTED:

12/11/2022 14:19:07

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR:

CLINICAL INFORMATION:

UID:2354747 REQNO-1319280

CORP-OPD

BILLNO-1501220PCR056893 BILLNO-1501220PCR056893

Test Report Status

Final

Results

Biological Reference Interval

Units

Dr.Akta Dubey

Counsultant Pathologist







Scan to View Report



(-)C	JG - Unconfirmed Diagnosis			
e normal early repol pattern	- NORMAL EC	avr		
69 . Sinus rhythm	AXIS P 71 QRS 67 T 31 12 Lead; Standard Placement	Pe -	Ac	

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF NIC

Date: 12/Nov/2022

Name: Mr. SUSHIL PRADHAN

Age | Sex: 34 YEAR(S) | Male

Order Station: FO-OPD

Bed Name:

UHID | Episode No : 2354747 | 56336/22/1501

Order No | Order Date: 1501/PN/OP/2211/119709 | 12-Nov-2022

Admitted On | Reporting Date: 12-Nov-2022 13:50:39

Order Doctor Name : Dr.SELF.

ECHOCARDIOGRAPHY TRANSTHORACIC

FINDINGS:

- No left ventricle regional wall motion abnormality at rest.
- Normal left ventricle systolic function. LVEF = 60%.
- No left ventricle diastolic dysfunction. No e/o raised LVEDP.
- · No mitral regurgitation.
- No aortic regurgitation. No aortic stenosis.
- Trivial tricuspid regurgitation. No pulmonary hypertension.
 PASP = 25 mm of Hg.
- · Intact IVS and IAS.
- No left ventricle clot/vegetation/pericardial effusion.
- · Normal right atrium and right ventricle dimension.
- Normal left atrium and left ventricle dimension.
- Normal right ventricle systolic function. No hepatic congestion.
- IVC measures 15 mm with normal inspiratory collapse.

M-MODE MEASUREMENTS:

LA	35	mm
AO Root	29	mm
AO CUSP SEP	18	mm
LVID (s)	31	mm
LVID (d)	43	
IVS (d)	10	mm
LVPW (d)	. 09	mm
RVID (d)	29	mm
RA	31	mm
LVEF	60	%

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN : 27AABCH5894D1ZG PAN NO : AABCH5894D





DEPARTMENT OF NIC

Date: 12/Nov/2022

Name: Mr. SUSHIL PRADHAN

Age | Sex: 34 YEAR(S) | Male

Order Station: FO-OPD

Bed Name:

UHID | Episode No: 2354747 | 56336/22/1501

Order No | Order Date: 1501/PN/OP/2211/119709 | 12-Nov-2022

Admitted On | Reporting Date: 12-Nov-2022 13:50:39

Order Doctor Name: Dr.SELF.

DOPPLER STUDY:

E WAVE VELOCITY: 0.9 m/sec. A WAVE VELOCITY: 0.8 m/sec

E/A RATIO: 1.1

		MEAN (mmHg)	GRADE OF REGURGITATION
MITRAL VALVE	N		Nil
AORTIC VALVE	05		Nil
TRICUSPID VALVE	25		Trivial
PULMONARY VALVE	2.0		Nil

Final Impression:

- · No RWMA.
- · Trivial TR. No PH.
- · Normal LV and RV systolic function.

DR. PRASMANT PAWAR, DNB(MED), DNB (CARDIOLOGY)

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN : 27AABCH5894D1ZG PAN NO : AABCH5894D





(For Billing/Reports & Discharge Summary only)

DEPARTMENT OF RADIOLOGY

Date: 12/Nov/2022

Name: Mr. SUSHIL PRADHAN

Age | Sex: 34 YEAR(S) | Male Order Station : FO-OPD

Bed Name:

UHID | Episode No : 2354747 | 56336/22/1501

Order No | Order Date: 1501/PN/OP/2211/119709 | 12-Nov-2022

Admitted On | Reporting Date: 12-Nov-2022 14:01:18

Order Doctor Name: Dr.SELF.

X-RAY-CHEST- PA

Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bilateral cervical ribs are noted. Rest of the bony thorax is unremarkable.

DR. YOGINI SHAH

DMRD., DNB. (Radiologist)

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF RADIOLOGY

Date: 12/Nov/2022

Name: Mr. SUSHIL PRADHAN

Age | Sex: 34 YEAR(S) | Male Order Station : FO-OPD

Bed Name:

UHID | Episode No : 2354747 | 56336/22/1501

Order No | Order Date: 1501/PN/OP/2211/119709 | 12-Nov-2022 Admitted On | Reporting Date : 12-Nov-2022 16:15:49

Order Doctor Name: Dr.SELF.

US-WHOLE ABDOMEN

LIVER is normal in size (12.4 cm) and shows raised echogenicity. Intrahepatic portal and biliary systems are normal. No focal lesion is seen in liver. Portal vein appears normal (9.2 mm).

GALL BLADDER is partially distended.

SPLEEN is normal in size and echogenicity.

BOTH KIDNEYS are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 9.9 x 4.4 cm.

Left kidney measures 9.8 x 4.5 cm.

PANCREAS is normal in size and morphology. No evidence of peripancreatic collection.

URINARY BLADDER is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical mass/calculi.

PROSTATE is normal in size & echogenicity. It measures ~ 10.1 cc in volume.

No evidence of ascites.

IMPRESSION:

Fatty infiltration of liver.

DR. YOGESH PATHADE (MD Radio-diagnosis)